Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Consensus Rating of “Moderate Buy” by Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) has been assigned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $8.50.

A number of equities analysts have weighed in on RANI shares. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of Rani Therapeutics in a report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rani Therapeutics in a report on Monday, December 29th. Finally, Maxim Group boosted their price target on Rani Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, October 20th.

Insider Activity

In related news, Director Mir A. Imran bought 2,083,334 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average cost of $0.60 per share, for a total transaction of $1,250,000.40. Following the acquisition, the director owned 2,083,334 shares in the company, valued at $1,250,000.40. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder South Cone Investments Limited sold 4,000,000 shares of Rani Therapeutics stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the sale, the insider owned 2,379,194 shares in the company, valued at $6,590,367.38. This represents a 62.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 26.51% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of RANI. Well Done LLC acquired a new stake in Rani Therapeutics during the 2nd quarter valued at approximately $27,000. Janney Montgomery Scott LLC boosted its stake in shares of Rani Therapeutics by 102.9% during the 2nd quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company’s stock valued at $28,000 after buying an additional 28,000 shares during the last quarter. Armistice Capital LLC acquired a new stake in shares of Rani Therapeutics during the second quarter worth approximately $1,619,000. CWA Asset Management Group LLC increased its stake in shares of Rani Therapeutics by 80.0% in the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after buying an additional 66,667 shares during the last quarter. Finally, Citadel Advisors LLC raised its holdings in Rani Therapeutics by 199.0% in the third quarter. Citadel Advisors LLC now owns 452,542 shares of the company’s stock valued at $226,000 after acquiring an additional 301,193 shares in the last quarter. Institutional investors and hedge funds own 30.19% of the company’s stock.

Rani Therapeutics Stock Up 0.7%

Shares of NASDAQ:RANI opened at $1.40 on Friday. The company has a market capitalization of $170.11 million, a P/E ratio of -1.77 and a beta of 0.42. Rani Therapeutics has a 52-week low of $0.39 and a 52-week high of $3.87. The stock’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.02.

Rani Therapeutics (NASDAQ:RANI) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.03). On average, sell-side analysts anticipate that Rani Therapeutics will post -1.01 earnings per share for the current year.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.